Logotyp: till Uppsala universitets webbplats

uu.sePublikationer från Uppsala universitet
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Methylation in MAD1L1 is associated with the severity of suicide attempt and phenotypes of depression
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kirurgiska vetenskaper, Funktionell farmakologi och neurovetenskap.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kirurgiska vetenskaper, Funktionell farmakologi och neurovetenskap.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kirurgiska vetenskaper, Funktionell farmakologi och neurovetenskap.
Umeå Univ, Dept Clin Sci Psychiat, Umeå, Sweden.;Karolinska Inst, Dept Womens & Childrens Hlth Neuropediat, Stockholm, Sweden..
Visa övriga samt affilieringar
2023 (Engelska)Ingår i: Clinical Epigenetics, E-ISSN 1868-7083, Vol. 15, artikel-id 1Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Depression is a multifactorial disorder representing a significant public health burden. Previous studies have linked multiple single nucleotide polymorphisms with depressive phenotypes and suicidal behavior. MAD1L1 is a mitosis metaphase checkpoint protein that has been linked to depression in GWAS. Using a longitudinal EWAS approach in an adolescent cohort at two time points (n = 216 and n = 154), we identified differentially methylated sites that were associated with depression-related genetic variants in MAD1L1. Three methylation loci (cg02825527, cg18302629, and cg19624444) were consistently hypomethylated in the minor allele carriers, being cross-dependent on several SNPs. We further investigated whether DNA methylation at these CpGs is associated with depressive psychiatric phenotypes in independent cohorts. The first site (cg02825527) was hypomethylated in blood (exp(beta) = 84.521, p value similar to 0.003) in participants with severe suicide attempts (n = 88). The same locus showed increased methylation in glial cells (exp(beta) = 0.041, p value similar to 0.004) in the validation cohort, involving 29 depressed patients and 29 controls, and showed a trend for association with suicide (n = 40, p value similar to 0.089) and trend for association with depression treatment (n = 377, p value similar to 0.075). The second CpG (cg18302629) was significantly hypomethylated in depressed participants (exp(beta) = 56.374, p value similar to 0.023) in glial cells, but did not show associations in the discovery cohorts. The last methylation site (cg19624444) was hypomethylated in the whole blood of severe suicide attempters; however, this association was at the borderline for statistical significance (p value similar to 0.061). This locus, however, showed a strong association with depression treatment in the validation cohort (exp(beta) = 2.237, p value similar to 0.003) with 377 participants. The direction of associations between psychiatric phenotypes appeared to be different in the whole blood in comparison with brain samples for cg02825527 and cg19624444. The association analysis between methylation at cg18302629 and cg19624444 and MAD1L1 transcript levels in CD14+ cells shows a potential link between methylation at these CpGs and MAD1L1 expression. This study suggests evidence that methylation at MAD1L1 is important for psychiatric health as supported by several independent cohorts.

Ort, förlag, år, upplaga, sidor
BioMed Central (BMC), 2023. Vol. 15, artikel-id 1
Nyckelord [en]
DNA methylation, Depression, Suicide
Nationell ämneskategori
Psykiatri Medicinsk genetik och genomik
Identifikatorer
URN: urn:nbn:se:uu:diva-495863DOI: 10.1186/s13148-022-01394-5ISI: 000908834800002PubMedID: 36600305OAI: oai:DiVA.org:uu-495863DiVA, id: diva2:1735407
Forskningsfinansiär
Vetenskapsrådet, K2009-61P-21304-04-4Uppsala universitetHjärnfondenVetenskapsrådet, K2009-61X-21305-01-1Region Västerbotten, VLL-582221Region Stockholm, SLL-20150269Tillgänglig från: 2023-02-08 Skapad: 2023-02-08 Senast uppdaterad: 2025-02-10Bibliografiskt granskad
Ingår i avhandling
1. Biomarkers for depression: genetic, epigenetic, and expression evidence
Öppna denna publikation i ny flik eller fönster >>Biomarkers for depression: genetic, epigenetic, and expression evidence
2024 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]

Depression is a very prevalent disorder affecting between 2 to 21% of the world population. This thesis extends the knowledge on the biological aspects of depression, aiming to identify and validate markers of genetic, epigenetic, and gene expression origin.

In Study I, the main focus was depression-related gene MAD1L1 that was previously linked to depression by SNPs and frequently mentioned as a stress-related marker. We identified that depression-related SNPs in MAD1L1 affect DNA methylation levels at cg02825527, cg18302629, and cg19624444 that were associated with depressive phenotypes in independent cohorts.

In Study II, we investigated whether GWAS catalog depression SNPs located in Olink-detectable genes could be replicated in a UKBiobank cohort and whether these associations are supported by DNA methylation and transcriptome. We validated eight depression SNPs and found very weak evidence that TNXB may be related to depression.

Study III was based on comparison of different depression -OMIC layers, including genetics, DNA methylation, and transcriptome. We explored how the identified genes from different -OMICs overlap, are functionally related and if they could show patterns in drugs and clinical trials. Only three genes were supported by evidence at all three -OMIC levels and included: FOXP1, VPS41, and AKTIP. Different -OMIC levels showed involvement of multiple systems in depression.

In Study IV, we used the Neuro Exploratory panel (Olink) to identify depression proteomic changes in blood. We took antidepressant intake into the account and validated associations in the independent datasets. We identified several proteins that showed nominally different levels between depression risk groups in the adolescent cohort. Validation of identified markers yielded that only PPP3R1 was also differentially expressed in prefrontal cortex and whole blood in the independent open-access cohorts with matching association directions.

In Study V, we used the entire blood DNA methylation as a depression marker. We investigated stability of DNA-methylation in eight independent datasets with meta-analysis and compared common machine learning and deep learning strategies for the depression detection purposes. We found 1987 CpG sites related to depression in both mega- and meta-analysis at the nominal level. Random forest classifiers achieved the best performance in identifying depression based on DNA methylation data in blood (AUC 0.73 and 0.76) in CV and hold-out tests respectively on the batch-level processed data.

Overall, the thesis supports multiple depression genetic, epigenetic, and expression markers. However, identified individual and systemic depression changes show high variability, which is in agreement with previous studies and observations.

Ort, förlag, år, upplaga, sidor
Uppsala: Acta Universitatis Upsaliensis, 2024. s. 98
Serie
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 2093
Nyckelord
Depression, Biomarkers, Epigenetics, DNA methylation, Proteomics, Transcriptomics, Genetics, Machine learning
Nationell ämneskategori
Bioinformatik (beräkningsbiologi) Psykiatri Neurovetenskaper
Forskningsämne
Psykiatri; Bioinformatik
Identifikatorer
urn:nbn:se:uu:diva-540129 (URN)978-91-513-2270-4 (ISBN)
Disputation
2024-12-04, room A1:111a, Uppsala biomedicinska centrum (BMC), Husargatan 3, Uppsala, 13:00 (Engelska)
Opponent
Handledare
Tillgänglig från: 2024-11-13 Skapad: 2024-10-10 Senast uppdaterad: 2024-11-13

Open Access i DiVA

fulltext(3761 kB)365 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 3761 kBChecksumma SHA-512
2c99c95f94e642d010daaf9af0d99c07feb9f4fd4607c951352624125013799c285553d05339713d3459a9d00d4aae45f6ca86165c2cc2364083bc0f758f5f2f
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMed

Person

Sokolov, Aleksandr V.Schiöth, Helgi B.

Sök vidare i DiVA

Av författaren/redaktören
Sokolov, Aleksandr V.Schiöth, Helgi B.
Av organisationen
Funktionell farmakologi och neurovetenskap
I samma tidskrift
Clinical Epigenetics
PsykiatriMedicinsk genetik och genomik

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 366 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 232 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf